{"nctId":"NCT04838626","briefTitle":"Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection","startDateStruct":{"date":"2021-09-07","type":"ACTUAL"},"conditions":["Prostatic Neoplasms","Prostate Cancer"],"count":195,"armGroups":[{"label":"PET/CT imaging with [18F]CTT1057","type":"EXPERIMENTAL","interventionNames":["Drug: [18F]CTT1057"]}],"interventions":[{"name":"[18F]CTT1057","otherNames":["Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Untreated high risk biopsy-proven PCa patients according to D'Amico classification (Stage ≥ T2c or PSA level \\>20ng/ml or Gleason score ≥8) (D'Amico et al 1998)\n* Scheduled or planned radical prostatectomy and extended pelvic lymph node resection up to 6 weeks after the investigational PET/CT scan followed by histopathology assessment\n* ECOG performance status 0-2\n* Signed informed consent must be obtained prior to participation in the study\n* Participants must be adults ≥ 18 years of age\n\nExclusion Criteria:\n\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.)\n* Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and COVID-19.\n* Known allergy, hypersensitivity, or intolerance to \\[18F\\]CTT1057\n* Prior and current use of PSMA targeted therapies\n* Prior and current treatment with any ADT (first or second generation), including LHRH analogues (agonists or antagonists)\n* Any 5-alpha reductase inhibitors within 30 days before screening\n* Patients with small cell or neuroendocrine PCa in more than 50% of biopsy tissue\n* Patients with incidental PCa after transurethral resection\n* Use of other investigational drugs within 30 days before screening","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity","description":"Sensitivity of vidoflufolastat (18F) Positron Emission Tomography (PET) imaging, considering Prostate Specific Membrane Antigen (PSMA) positive patients as those who show at least one pathological vidoflufolastat (18F) uptake either in the primary tumor and/or metastatic Pelvic Lymph Node (PLN) regions, with anatomically localized correspondence with the Standard of Truth (SoT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"88.2","spread":null},{"groupId":"OG002","value":"86.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Region-level Specificity of Vidoflufolastat (18F) - % Specificity","description":"Specificity of vidoflufolastat (18F) PET imaging, defined as proportion of PLN regions that test negative for lymph nodes on vidoflufolastat (18F) among those that are lymph node negative on the SoT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.1","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"97.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Specificity of Vidoflufolastat (18F) - % Specificity","description":"Specificity of vidoflufolastat (18F) PET imaging, considering PSMA negative patients as those who do not show any pathological vidoflufolastat (18F) uptake either in the primary tumor or PLNs and will be confirmed not having primary tumor or metastatic PLNs with the SoT","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"20.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Positive Predictive Value of Vidoflufolastat (18F)","description":"Proportion of patients who are both vidoflufolastat (18F) and SoT positive (true positives (TP) among those who test positive on vidoflufolastat (18F) (TP+ false positives (FP))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"98.7","spread":null},{"groupId":"OG002","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Negative Predictive Value of Vidoflufolastat (18F)","description":"Proportion of patients who are both vidoflufolastat (18F) and SoT negative (true negatives (TN)) among those who test negative on vidoflufolastat (18F) (TN+ false negatives (FN))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient-level Accuracy of Vidoflufolastat (18F)","description":"Proportion of patients that are SoT and vidoflufolastat (18F) positive (TP) and negative (TN) among all patients in Efficacy Analysis Set (EFF) (TP+TN+FP+FN)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.2","spread":null},{"groupId":"OG001","value":"87.2","spread":null},{"groupId":"OG002","value":"84.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity","description":"Proportion of PLN regions that test positive on both vidoflufolastat (18F) and SoT (TP) among those that are SoT positive (TP+FN)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"23.5","spread":null},{"groupId":"OG002","value":"20.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Positive Predictive Value of Vidoflufolastat (18F)","description":"Proportion of Pelvic Lymph Node (PLN) regions that are Standard of Truth (SoT) and vidoflufolastat (18F) positive (TP) among those regions that test positive on vidoflufolastat (18F) (TP+False Positive (FP))","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"63.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Negative Predictive Value of Vidoflufolastat (18F)","description":"Proportion of PLN regions that are SoT and vidoflufolastat (18F) negative (TN) among those regions that test negative on vidoflufolastat (18F) (TN+FN)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"83.8","spread":null},{"groupId":"OG002","value":"83.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Accuracy of Vidoflufolastat (18F)","description":"Proportion of PLN regions that are SoT and vidoflufolastat (18F) positive (TP) and negative (TN) among all PLN regions assessed vidoflufolastat (18F)(TP+TN+FP+FN)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"82.6","spread":null},{"groupId":"OG002","value":"82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Region-level Sensitivity of Vidoflufolastat (18F) Scan With Standard of Truth Excluding Pelvic Lymph Node (PLN) Metastasis < 2 mm","description":"Sensitivity of vidoflufolastat (18F) PET imaging in the PLN region, excluding from the analysis those lymph nodes showing metastasis \\<2mm (micro-metastasis)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":null},{"groupId":"OG001","value":"30.8","spread":null},{"groupId":"OG002","value":"26.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Distant Metastasis of Vidoflufolastat (18F) Scan - Participants With at Least One Distant Metastatic Lesion (%)","description":"Number of distant metastasis identified at PET/CT scan in all patients, and percentage of patients with at least one distant metastatic lesion (extra-PLN, visceral or skeletal)identified by PET scan in all patients with an evaluable vidoflufolastat (18F) PET/CT scan.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overview of Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \\[including abnormal laboratory findings\\], symptom or disease) in a subject or clinical investigation subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Vidoflufolastat (18F) Scan Inter-reader Variability - %","description":"Scan inter-reader variability is defined the agreement rate among reader determination of vidoflufolastat (18F) images.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Vidoflufolastat (18F) Scan Inter-reader Variability - Number of Scans Agreed","description":"Scan inter-reader variability is defined the agreement rate among reader determination of vidoflufolastat (18F) images.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Vidoflufolastat (18F) Scan Intra-reader Variability","description":"Scan intra-reader variability is defined as the within-reader agreement rate of vidoflufolastat (18F) images.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"89.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Maximum Blood Concentration (Cmax) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":"19.2"}]}]}]},{"type":"SECONDARY","title":"Time of Maximum Observed Blood Concentration Occurrence (Tmax) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0333","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Vidoflufolastat (18F) Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":"11.9"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUCinf) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Half-Life Lambda z of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution During the Terminal Phase Following Intravenous Elimination (Vz) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Urinary Excretion of Radioactivity Expressed as a Percentage of Injected Activity (%IA) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000821","spread":"0.00120"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"11.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"8.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"8.06"}]}]}]},{"type":"SECONDARY","title":"Total Systemic Clearance for Intravenous Administration (CL) of Vidoflufolastat (18F)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.70","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":184},"commonTop":["Hypertension","Dizziness","Presyncope","Abdominal pain","Diarrhoea"]}}}